FDA is open to accepting less data for antibiotics than that provided by two Phase III trials if the drugs target infections caused by drug-resistant bacteria for which there are few therapeutic options.
A “more limited development program holds promise as a pathway for the development of new drugs for those patients for...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?